Amgen Inc. (AMGN) Position Increased by Kelman Lazarov Inc.
Kelman Lazarov Inc. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,580 shares of the medical research company’s stock after buying an additional 120 shares during the period. Kelman Lazarov Inc.’s holdings in Amgen were worth $272,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the stock. First Command Financial Services Inc. increased its stake in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock worth $254,000 after buying an additional 17 shares in the last quarter. Prospera Financial Services Inc increased its stake in Amgen by 36.6% in the first quarter. Prospera Financial Services Inc now owns 2,829 shares of the medical research company’s stock worth $462,000 after buying an additional 758 shares in the last quarter. Private Trust Co. NA increased its stake in Amgen by 16.4% in the first quarter. Private Trust Co. NA now owns 7,092 shares of the medical research company’s stock worth $1,163,000 after buying an additional 999 shares in the last quarter. Honkamp Krueger Financial Services Inc. increased its stake in Amgen by 4.7% in the first quarter. Honkamp Krueger Financial Services Inc. now owns 5,327 shares of the medical research company’s stock worth $874,000 after buying an additional 239 shares in the last quarter. Finally, Oakmont Partners LLC purchased a new stake in Amgen during the first quarter worth $989,000. 78.12% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.78% during midday trading on Wednesday, hitting $173.57. The stock had a trading volume of 770,993 shares. The stock’s 50-day moving average is $173.53 and its 200-day moving average is $168.31. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21. The stock has a market cap of $126.65 billion, a PE ratio of 15.81 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the previous year, the firm posted $2.84 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Equities analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.67%. Amgen’s dividend payout ratio is currently 41.93%.
A number of research firms have weighed in on AMGN. BMO Capital Markets downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Deutsche Bank AG restated a “hold” rating and set a $174.00 price target (up from $172.00) on shares of Amgen in a report on Wednesday, July 26th. Cann restated a “buy” rating and set a $203.00 price target (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. Finally, Cowen and Company restated an “outperform” rating and set a $209.00 price target on shares of Amgen in a report on Saturday, July 22nd. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Amgen has a consensus rating of “Buy” and an average price target of $186.04.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.